文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性中治疗-延长方案与每月方案对比:TREND研究中雷珠单抗的结果

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
PubMed 文献 · Ophthalmology · 2017-10-12

TREND研究为12个月3b期、视力评估者设盲、多中心、随机、干预性研究,纳入650例未治疗的新生血管性年龄相关性黄斑变性患者,1:1随机接受雷珠单抗0.5 mg治疗-延长方案(n=323)或每月方案(n=327)。治疗-延长方案在最佳矫正视力从基线至研究结束的变化上非劣于每月方案(最小二乘均值6.2 vs 8.1个字母,P<0.001),注射次数更少(8.7 vs 11.1次),不良事件类型和发生率相当。

要点

  • 治疗-延长方案在视力改善上非劣于每月方案(最小二乘均值6.2 vs 8.1个字母,P<0.001)。
  • 治疗-延长方案所需注射次数为8.7次,少于每月方案的11.1次。
  • 两组不良事件类型和发生率相当,未发现雷珠单抗新的安全性信号。

核心结论

  • 雷珠单抗0.5 mg按治疗-延长方案给药在改善视力方面统计学非劣且临床可与每月方案媲美。
  • 未发现雷珠单抗新的安全性信号。

研究设计与样本

  • 12个月3b期、视力评估者设盲、多中心、随机、干预性研究。
  • 共纳入650例未治疗的新生血管性年龄相关性黄斑变性患者(年龄≥50岁),1:1随机接受雷珠单抗0.5 mg治疗-延长方案(n=323)或每月方案(n=327)。

主要发现

  • 治疗-延长方案组89.8%、每月方案组90.2%的患者完成研究。
  • 治疗-延长方案非劣于每月方案(P<0.001),从基线至研究结束的最佳矫正视力最小二乘均值变化分别为6.2个字母与8.1个字母。
  • 两组最佳矫正视力改善大多发生在最初6个月并维持至研究结束。
  • 从基线至研究结束的视网膜中央子区域厚度平均变化在治疗-延长方案组为-169.2 μm、每月方案组为-173.3 μm。
  • 治疗-延长方案组所需注射次数为8.7次,少于每月方案组的11.1次;基线后平均随访次数分别为8.9次与11.2次。

关键数值与推荐

  • 主要目标为通过从基线至研究结束的最佳矫正视力变化评估雷珠单抗0.5 mg治疗-延长方案相对每月方案的非劣效性。
  • 治疗-延长方案非劣效性检验P<0.001。
  • 两组不良事件类型和发生率相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E) versus monthly regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat and extEND (TREND) study. DESIGN: A 12-month phase 3b visual acuity (VA) assessor-masked, multicenter, randomized, interventional study. PARTICIPANTS: Six hundred fifty patients. METHODS: Treatment-naïve nAMD patients (age, ≥50 years) were randomized 1:1 to receive either a ranibizumab 0.5 mg T&E (n = 323) or monthly (n = 327) regimen. MAIN OUTCOMES MEASURES: The primary objective was to show noninferiority of ranibizumab 0.5 mg T&E versus monthly regimen, as assessed by the change in best-corrected VA (BCVA) from baseline to the end of the study. Secondary objectives included change in retinal central subfield thickness (CSFT) from baseline to the end of study, treatment exposure, and safety. RESULTS: Overall, 89.8% (T&E) and 90.2% (monthly) of patients completed the study. Patient demographic and baseline characteristics were well balanced between the 2 treatment groups. The T&E regimen was noninferior (P < 0.001) to the monthly regimen, with a least squares mean BCVA change from baseline of 6.2 versus 8.1 letters to the end of study, respectively. In both treatment groups, most BCVA improvements occurred during the first 6 months and were maintained until the end of the study. The mean change in CSFT from baseline to the end of study was -169.2 μm and -173.3 μm in the T&E and monthly groups, respectively. Fewer injections were required in patients receiving the T&E (8.7) versus monthly (11.1) regimen, with mean number of postbaseline visits of 8.9 and 11.2, respectively. Types and rates of adverse events were comparable between the treatment groups. CONCLUSIONS: Ranibizumab 0.5 mg administered according to a T&E regimen was statistically noninferior and clinically comparable with a monthly regimen in improving VA from baseline to the end of study. No new safety signals for ranibizumab were identified.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Silva R, Berta A, Larsen M, et al. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study. Ophthalmology. 2017. PMID: 28893454. doi:10.1016/j.ophtha.2017.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。